Telitacicept + Placebo

Phase 3Recruiting

0 views this week 0 watching⚡ Active🔬Featured in Small-Cap Pipeline Watch

Interest: 41/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Generalized Myasthenia Gravis

Conditions

Generalized Myasthenia Gravis

Trial Timeline

Jul 17, 2024 → Jan 1, 2029

NCT ID

NCT06456580

About Telitacicept + Placebo

Telitacicept + Placebo is a phase 3 stage product being developed by Vor Biopharma for Generalized Myasthenia Gravis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06456580. Target conditions include Generalized Myasthenia Gravis.

What happened to similar drugs?

6 of 20 similar drugs in Generalized Myasthenia Gravis were approved

Approved (6) Terminated (3) Active (12)

❌SatralizumabChugai PharmaceuticalPhase 3

🔄Perampanel + Placebo comparatorEisaiPhase 3

🔄PerampanelEisaiPhase 3

🔄CenobamateOno PharmaceuticalPhase 3

🔄Duloxetine + PlaceboEli LillyPhase 3

✅Duloxetine + PlaceboEli LillyApproved

✅IxekizumabEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07404865	Phase 3	Recruiting	Feb 26, 2026	Aug 1, 2028	Primary Sjogren's Disease
NCT06456567	Phase 3	Withdrawn	Sep 1, 2024	Jan 6, 2025	Systemic Lupus Erythematosus
NCT06456580	Phase 3	Recruiting	Jul 17, 2024	Jan 1, 2029	Generalized Myasthenia Gravis
NCT05306574	Phase 3	Terminated	Jun 20, 2022	Jan 6, 2025	Systemic Lupus Erythematosus

Competing Products

20 competing products in Generalized Myasthenia Gravis

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + placebo	Eli Lilly	Phase 2/3	38
Satralizumab	Chugai Pharmaceutical	Phase 3	32
Perampanel	Eisai	Pre-clinical	26
Perampanel + Placebo comparator	Eisai	Phase 3	40
zonisamide	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Cenobamate	Ono Pharmaceutical	Phase 3	47
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
Ixekizumab	Eli Lilly	Approved	43
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	43
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	27
ABBV-932 + Placebo	AbbVie	Phase 1	29
Escitalopram	AbbVie	Approved	43
Adalimumab	AbbVie	Phase 3	40